US regulators have asked Novavax to conduct another clinical trial of its Covid vaccine, prompting a 13% drop in the company’s shares. This request comes as part of a “post-marking commitment” by the FDA, seeking more data on the safety and efficacy of the product after it has been approved. The news was reported by the Wall Street Journal on Friday, marking a significant development in the ongoing vaccine development landscape.
Source: https://www.bloomberg.com/news/articles/2025-04-25/novavax-falls-on-report-that-fda-wants-new-covid-vaccine-trial